
|Videos|January 23, 2018
Establishing a Support System
Advertisement
Episodes in this series

Advertisement
Related to this article

See how FDA-approved lymphoma treatments have changed over 5 years — what's new, who it's helped, and what's still to come.

Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.

An expert discusses August's FDA approvals for myeloma, polycythemia vera and essential thrombocythemia, plus first-line myeloma care and MRD testing.

Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.

CURE spoke with Oncology Aesthetics & Wellness founder, Deborah A. McDowell, about hair preservation before, during and after cancer treatment.

A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.

A wife reflects on her husband’s cancer treatment, finding comfort, hope and connection in their simple ritual of sharing bagels before each treatment.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Welireg Plus Lenvima for Advanced Kidney Cancer After Immunotherapy
2
What to Do Before Your Chemo Infusion: A Checklist From People Who've Been There
3
7 Breast Cancer Clinical Trials Currently Enrolling in the US
4
How Paxalisib Targets Treatment Resistance in Breast Cancer
5














